IGIH19161, Hezel, NuTide:121, Hepatoboliary, NUC-1031
Research Question:
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin,
in patients with previously untreated advanced biliary tract cancer.
Basic Study Information
Purpose:
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin,
in patients with previously untreated advanced biliary tract cancer.
The primary hypotheses are:
The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the
gemcitabine plus cisplatin standard of care
The combination of NUC-1031 plus cisplatin increases overall response rate compared
to the gemcitabine plus cisplatin standard of care
Location: University of Rochester Medical Center
Study Reference #: IGIH19161
Lead Researcher (Principal Investigator)
Lead Researcher:
Aram Hezel
Study Contact Information
Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search